VelaVigo宣布第二项对外授权协议，涉及一款首创的双特异性抗体，进一步验证了其创新发现平台及可持续的BD+VC商业模式-动脉网

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model

CISION 等信源发布 2025-04-18 08:00



可切换为仅中文







SHANGHAI

上海

and

和

BOSTON

波士顿

，

April 17, 2025

2025年4月17日

/PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate (ADC), today announced its second out-licensing agreement of a first-in-class (FIC) asset to Ollin Biosciences, Inc.

/PRNewswire/ -- VelaVigo Bio，VelaVigo Cayman Limited（VelaVigo）的美国子公司，一家拥有强大多特异性抗体和抗体药物偶联物（ADC）发现与开发平台的生物技术公司，今日宣布已与Ollin Biosciences, Inc.达成一项首创新药（FIC）资产的第二次对外授权协议。

('Ollin'), granting Ollin an exclusive license to develop, manufacture and commercialize VBS-102, a first-in-class bispecific antibody, globally (excluding .

（“Ollin”），授予Ollin独家许可，用于开发、生产和商业化VBS-102，一种全球首创的双特异性抗体，覆盖全球（排除特定地区）。

Greater China

大中华区

). VelaVigo will maintain rights for

）。VelaVigo 将保留权利用于

Greater China

大中华区

。

Under the terms of the agreement, VelaVigo will receive an upfront fee and future development, regulatory, and commercial milestone payments in cash and equity, totaling up to approximately

根据协议条款，VelaVigo将获得一笔预付款，并在未来获得现金和股权形式的开发、监管和商业里程碑付款，总额高达约

$440 million

4.4亿美元

in the aggregate, as well as tiered royalties on sales in Ollin's territory.

总体而言，以及在Ollin领域的销售中收取的分级特许权使用费。

This milestone follows VelaVigo's first licensing deal with Avenzo Therapeutics in

这一里程碑紧随VelaVigo与Avenzo Therapeutics的首项许可协议之后。

November 2024

2024年11月

and the successful close of a

成功结束一个

$50 million

5000万美元

Pre-A funding round in

Pre-A轮融资在

February 2025

2025年2月

, reinforcing the company's unique business model combining business development (BD) and venture capital (VC) strategies for sustainable growth.

，强化了公司结合业务发展（BD）和风险投资（VC）策略以实现可持续增长的独特商业模式。

The latest deal underscores VelaVigo's ability to discover and develop high-potential therapeutics while partnering strategically to maximize value. Additionally, VelaVigo is advancing its fully owned lead asset, a FIC/BIC bispecific ADC, into a U.S. clinical trial this year and expanding its global clinical development capabilities.

最新的协议突显了VelaVigo 发现和开发高潜力疗法的能力，同时通过战略性合作实现价值最大化。此外，VelaVigo 正在将其全资拥有的领先资产（一种 FIC/BIC 双特异性 ADC）推进到今年的美国临床试验，并扩展其全球临床开发能力。

The company will also present data on five additional FIC or BIC molecules at upcoming industry conferences, seeking further partnership opportunities worldwide..

该公司还将在即将举行的行业会议上展示另外五个首创（FIC）或同类最佳（BIC）分子的数据，寻求在全球范围内进一步的合作机会。

'This second out-licensing deal is a strong validation of our discovery platform and our ability to identify and advance novel therapeutics with significant potential,'

“这项第二次对外授权交易有力地验证了我们的发现平台，以及我们识别和推进具有重大潜力的新型疗法的能力。”

said

说

Jing Li

李静

, CEO of VelaVigo.

，VelaVigo首席执行官。

'With our first asset entering the clinic this year and a deep pipeline of innovative molecules, we are demonstrating our capacity to translate cutting-edge science into valuable clinical-stage programs. Our goal is to build a global biotech leader by leveraging strategic partnerships while advancing our own portfolio.'.

“随着我们首个资产今年进入临床，以及众多创新分子的深厚管线，我们正在展示将前沿科学转化为有价值的临床阶段项目的能力。我们的目标是通过利用战略合作伙伴关系，在推进自身产品组合的同时，打造一家全球生物技术领导者。”

'Our BD+VC model is designed to create sustainable value for investors and partners,'

“我们的BD+VC模型旨在为投资者和合作伙伴创造可持续的价值，”

said Tong Zhang, co-founder, Chief Business & Financial Officer of VelaVigo.

张彤，VelaVigo联合创始人、首席业务和财务官表示。

'This second licensing deal, following our successful

“继我们成功达成的第二个许可协议，

$50M

5000万美元

Pre-A round, highlights our ability to execute on both financing and strategic collaborations. We are actively engaging with potential partners to expand our global footprint and accelerate the development of our pipeline.'

A轮融资前，凸显了我们在融资和战略协作方面的执行能力。我们正在积极与潜在合作伙伴接洽，以扩大我们的全球足迹并加速推进我们的产品管线开发。

About VelaVigo

关于VelaVigo

VelaVigo is a leading antibody/ADC discovery and development biotech company with a highly efficient discovery engine and strong capabilities in translational medicine, CMC and early clinical development. Its leading products, the FIC bispecific ADCs, are expected to enter clinical development in the US and .

VelaVigo是一家领先的抗体/ADC发现与开发生物技术公司，拥有高效的发现引擎，并在转化医学、CMC和早期临床开发方面具备强大的能力。其领先产品FIC双特异性ADC预计将在美国进入临床开发阶段。

China

中国

in 2025. VelaVigo continues to build capabilities in clinical development, technology platforms, and partnership with biopharmaceutical companies and investors globally to maximize the efficiency of drug development and return on investment.

2025年，维拉维戈将继续在临床开发、技术平台以及与全球生物制药公司和投资者的合作方面提升能力，以最大化药物开发的效率和投资回报率。

VelaVigo was founded in 2021 with a

VelaVigo 成立于 2021 年，

$50M

5000万美元

investment, its R&D centers in

投资，其研发中心在

Shanghai

上海

, and clinical and US operations in

，以及临床和美国的运营在

Boston